With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research exposes far-reaching toll of financial hardship on patients with cancer

2.

Because of the Medicare mail-order drug rule, oncologists run the risk of self-referral violations.

3.

Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers

4.

Watch for Psoriasis After Cancer Immunotherapy, Study Says

5.

High levels of traumatic stress found in caregivers of adult cancer patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot